Comerica Bank’s Tvardi Therapeutics TVRD Stock Holding History

Comerica Bank’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$4	Hold	1	–	–	﹤0.01%	3708
2025 Q3	$39	Hold	1	–	–	﹤0.01%	3701
2025 Q2	$23	Hold	1	–	–	﹤0.01%	3684
2025 Q1	$15	Hold	1	–	–	﹤0.01%	3679
2024 Q4	$20	Hold	1	–	–	﹤0.01%	3664
2024 Q3	$12	Hold	1	–	–	﹤0.01%	3666
2024 Q2	$10	Hold	1	–	–	﹤0.01%	3697
2024 Q1	$36	Hold	1	–	–	﹤0.01%	3731
2023 Q4	$30	Sell	1 -1	-50%	-$41	﹤0.01%	3719
2023 Q3	$127	Buy	+2	New	+$188	﹤0.01%	3770
2022 Q4	$285K	Sell	740 -202	-21%	-$76.7K	﹤0.01%	1976
2022 Q3	$333K	Sell	942 -53	-5%	-$19.2K	﹤0.01%	1922
2022 Q2	$345K	Buy	995 +15	+2%	+$5.26K	﹤0.01%	1956
2022 Q1	$461K	Sell	980 -31	-3%	-$12.7K	﹤0.01%	1899
2021 Q4	$429K	Sell	1,011 -52	-5%	-$26.1K	﹤0.01%	1920
2021 Q3	$486K	Sell	1,063 -57	-5%	-$28.6K	﹤0.01%	1954
2021 Q2	$500K	Buy	+1,120	New	+$710K	﹤0.01%	2026

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Comerica Bank's TVRD Position: Q4 2025 in Review

Comerica Bank held its Tvardi Therapeutics (TVRD) position steady in Q4 2025 at 1 share worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #3708.

Comerica Bank first reported a position in TVRD in Q2 2021 and has held it in 17 quarters since. The position peaked at $500K in Q2 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

Comerica Bank held 1 share of Tvardi Therapeutics worth $4 as of Q4 2025.
Comerica Bank left its Tvardi Therapeutics share count unchanged in Q4 2025.
Tvardi Therapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3708 holding.
Comerica Bank first reported a position in Tvardi Therapeutics in Q2 2021 and has held it in 17 quarters since.
Comerica Bank's Tvardi Therapeutics position peaked at $500K in Q2 2021.
67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.